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Changes in subcellular doxorubicin distribution and cellular accumulation
alone can largely account for doxorubicin resistance in SW-1573 lung
cancer and MCF-7 breast cancer multidrug resistant tumour cells
G.J. Schuurhuis 5, T.H.M. van Heijningen', A. Cervantes"6, H.M. Pinedo 4, J.H.M. de Lange2,
H.G. Keizer37, H.J. Broxterman', J.P.A. Baak2 & J. Lankelmal
Departments of'Medical Oncology, 2Quantitative Pathology, 'Human Genetics, The Free University and 4The Netherlands Cancer
Institute.
Summary Doxorubicin accumulation defects in multidrug reistant tumour cells are generally small in
comparison to the resistance factors. Therefore additional mechanisms must be operative. In this paper we
show by a quantitative approach that doxorubicin resistance in several P-glycoprotein-positive non-small cell
lung cancer and breast cancer multidrug resistant cell lines can be explained by a summation of accumulation
defect and alterations in the efficacy of the drug once present in the cell. This alteration of efficacy was partly due to changes in intracellular drug localisation, characterised by decreased nuclear/cytoplasmic doxorubicin
fluorescence ratios (N/C-ratios). N/C-ratios were 2.8-3.6 in sensitive cells, 0.1-0.4 in cells with high (>70-
fold) levels of doxorubicin resistance and 1.2 and 1.9 in cells with low or intermediate (7.5 and 24-fold,
respectively) levels of doxorubicin resistance. The change of drug efficacy was reflected by an increase in the
total amount of doxorubicin present in the cell at equitoxic (IC50) concentrations. N/C ratios in highly
resistant P-glycoprotein-containing cells could be increased with the resistance modifier verapamil to values of
1.3-2.7, a process that was paralleled by a decrease of the cellular doxorubicin amounts present at IC50. At
the low to moderate residual levels of resistance, obtained with different concentrations of verapamil, a linear
relationship between IC50 and cellular doxorubicin amounts determined at IC50 was found. This shows that at
this stage of residual resistance, extra reversal by verapamil should be explained by further increase of drug
efficacy rather than by increase of cellular drug accumulation. A similar relationship was found for P-
glycoprotein-negative MDR cells with low levels of resistance. Since in these cells N/C ratios could not be
altered, verapamil-induced decrease of IC50 must be due to increased drug efficacy by action on as yet
unidentified targets. Although the IC50 of sensitive human cells cannot be reached with resistance modifiers,
when using these relationships it can be shown by extrapolation that cellular and nuclear doxorubicin amounts
at IC50 at complete reversal of resistance were the same as in sensitive cells. It is concluded that doxorubicin
resistance factors for multidrug resistant cells can for a large part, and in the case ofP-glycoprotein-containing
cells probably fully, be accounted for by decreased amounts of drug at nuclear targets, which in turn is
characterised by two processes only: decreased cellular accumulation and a shift in the ratio nuclear
drug/cytoplasmic drug.
Expression of the putative drug efflux pump P- glycoprotein
in multidrug resistant (MDR) cells results in lower drug
accumulation than in the corresponding parent cells (Bradley
et al., 1988). Reduced drug accumulation may also be a
parameter of drug resistance for some (Coley et al., 1991;
Haber et al., 1989; Hindenburg et al., 1989; Kuiper et al.,
1990; McGrath & Center, 1988; Slapak et al., 1990; Slovak et
al., 1988; Taylor et al., 1991) but not for all (Cole et al.,
1991; Danks et al., 1987; Harker et al., 1989; McGrath et al.,
1989) MDR cells which do not overexpress P-glycoprotein.
Effective modulation of multidrug resistance is possible in P-
glycoprotein containing cells with compounds which exhibit
different structural features (Zamora et al., 1988) and it is
attributed to increases in cellular drug accumulation resulting
from inhibition of drug efflux (Bradley et al., 1988). Modula-
tion ofnon-P-glycoprotein mediated MDR and accumulation
defects by verapamil and other Pgp modulators, however,
seems to be less efficient than for P-glycoprotein mediated
MDR (Cole et al., 1989; Coley et al., 1991; Harker et al.,
1989; Kuiper et al., 1990; Schuurhuis et al., 1991; Slovak et
al., 1988; Taylor et al., 1991).
It is known that changes in drug accumulation can not
fully account for anthracycline resistance in many MDR cells
(evidence reviewed by Schuurhuis et al., 1989a). Such con-
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siderations have led to the suggestion that other mechanisms
must contribute to the MDR phenotype. One of the pos-
sibilities would be that enzymes, involved in the detoxifi-
cation of oxygen- derived free radicals generated by semi-
quinone compounds like doxorubicin, such as glutathione
transferase and glutathione peroxidase, contribute to
anthracycline resistance in MDR cells (Batist et al., 1986;
Cowan et al., 1986). MDR human breast cancer MCF-7ADR
cells have been studied in depth as to this and it was found
that doxorubicin-induced oxygen free radical formation was
strongly reduced compared to sensitive cells (Sinha et al.,
1987). Further, changes in levels and/or activity of
topoisomerase II may contribute to anthracycline and VP-16-
213 resistance (Beck, 1989). Another important phenomenon
associated with MDR is an altered intracellular drug dis-
tribution. Several studies now have shown that the develop-
ment of MDR is associated with a relative shift of doxo-
rubicin or daunorubicin fluorescence from the nucleus to the
cytoplasm (Broxterman et al., 1990; Gervasoni et al., 1991;
Gigli et al., 1989; Hindenburg et al., 1987, 1989; Keizer et al.,
1989; Schuurhuis et al., 1989a, 1991; Willingham et al.,
1986). In previous work with Chinese hamster ovarian cells
we have argued that this shift may contribute for an impor-
tant part to the ineffectiveness of anthracyclines in MDR
cells (Schuurhuis et al., 1989a).
We now extend these drug distribution studies using
various human MDR cells, including MCF-7ADR cells. With a
simple mathematical approach we show that doxorubicin
resistance in these P-glycoprotein-containing cells is deter-
mined mainly by reduced access to nuclear targets which in
turn is characterised by two factors only: reduced drug
accumulation and altered subcellular drug distribution.
Thereby the need is excluded to postulate that other
mechanisms contribute significantly to resistance. In addition,
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reversal of resistance in P- glycoprotein/MDR by verapamil
is related to effects on these factors. It is further shown that
in non-P-glycoprotein/MDR cell lines verapamil exerts part
of its effects via a third mechanism different from drug
accumulation or distribution.
Part of this work has been presented in preliminary form
at the 80th Annual Meeting of the American Association for
Cancer Research (Schuurhuis et al., 1989b).
Materials and methods
Drugs
Verapamil. HCI and colchicine were obtained from Sigma
(St. Louis, MO) and doxorubicin from Farmitalia (Italy).
[14-'4C]doxorubicin (50 Ci Mol'1) was purchased from
Amersham (Little Chalfont, UK). Drugs were added from
concentrated solutions in 0.9% sodium chloride.
Cells and cell culture
The Human non small cell lung cancer cell line SW-1573
(originally established by Dr A. Leibowitz, Scott and White
Clinic, Temple, TX) was exposed to increasing concentra-
tions of doxorubicin resulting in the MDR variants SW-
1573/1R50 and SW-1573/1R500 (Keizer et al., 1989) and the
SW-1573/2R30 cells, which were selected independently. SW-
1573/2R30 cells showed instable resistance and finally
resulted in the SW-1573/2R50 cells described earlier (Baas et
al., 1990; Kuiper et al., 1990). The partially revertant cell line
SW-1573/1R500-0 was obtained by culturing SW-1573/1R500
cells in drug-free medium as described (Keizer et al., 1989).
Resistance factors for doxorubicini as measured in a 2 h
incubation assay (see below) were 345 (SW-1573/lR500), 24
(SW-1573/1R500-0), 7.5 (SW-1573/1R50) and 4.8 (SW-1573/
2R30). The Chinese hamster ovarian cell line AUXB1 and its
MDR cell line CHRC5 were a gift from Dr V. Ling (Ontario
Cancer Institute, Ontario, Canada) and were cultured in
ocMEM. The human breast cancer cell line MCF-7 and its
MDR subline MCF- 7ADR were kindly provided by Dr K.
Cowan (National Cancer Institute, Bethesda, MD). The
human ovarian cancer A2780 cells were from the National
Cancer Institute (Dr R.F. Ozols). Lung, breast and ovarian
cancer cells were grown in Dulbecco's modication of Eagle's
medium (DMEM, Gibco, Europe Ltd, UK), containing
20 mM HEPES and supplemented with 10% foetal bovine
serum (Flow Laboratories, UK). MDR cells were grown in
the presence of drug until 1-2 weeks before experiments:
0.5 jM (SW-1573/1R500), 0.05fM (SW-1573/1R50), 0.03pM
(SW-1573/2R30), 101M (MCF-7ADR) and 2 fM (2780AD)
doxorubicin and 10figmlh' colchicine (CHRC5). Cell doub-
ling times (standard deviations: <15%) were: 24 h (SW-
1573), 27 h (SW-1573/1R50 and SW-1573/2R30), 30 h (SW-
1573/1R500 and SW-1573/1R500-0), 14 h (AUXBl), 24 h
(CHRC5), 24 h (MCF-7), 36 h (MCF-7ADR), 17 h (A2780) and
24 h (2780AD). All the MDR cell lines except SW-1573/1R50
and SW-i 573/2R30 were P-glycoprotein positive (Baas et al.,
1990; Fairchild et al., 1987; Keizer et al., 1989; Kuiper et al.,
1990; Scheper et al., 1988).
Drug cytotoxicity
Cytostatic effects were assessed essentialy as described
previously (Schuurhuis et al., 1987). Cells were plated in
6-well tissue clusters (Costar, USA) and incubated in the
presence of doxorubicin with or without verapamil for 2 h at
37C. A post-incubation of 24 h with verapamil was applied
in order to increase its modulating effect by inhibition of
doxorubicin efflux. After that treatment cells were incubated
for at least three doubling times and counted. Verapamil, at
the highest concentration used (128pM), inhibited cell growth
at 30% maximally. In all cases modulating effects of different
concentrations ofverapamil on doxorubicin cytotoxicity were
determined using cell growth in the presence of verapamil,
but without doxorubicin present, as the 100% control.
Drug accumulation
Log-phase trypsinised cells were suspended in growth
medium without NaHCO3 and phenol red but containing
20 mM HEPES, pH 7.4. Cellular doxorubicin accumulation
was measured with [14-'4C] doxorubicin after a 2 h incuba-
tion period at 37°C as described (Schuurhuis et al., 1987). No
corrections were made for direct binding of doxorubicin to
the cells (less than 20% at concentrations up to at least
2pM). In the case of CHRC5 and AUXB1 cells doxorubicin
accumulation was measured on cells adhered to 6-well culture
clusters. In those cases cells were washed three times with
0.1 M phosphate buffered saline, pH 7.4 after the incubation
period and thereafter trypsinised and counted. Controls
included wells without cells, but incubated with drugs.
Determination ofcellular and nuclear diameters
Diameters of trypsinised cells were determined using a Elzone
Electrozone/Celloscope, type 8OXY (Particle Data, Inc., Elm-
hurst, Ill.) Orifice diameter was 120tLM. Nuclei from different
SW-1573 cells were isolated by homogenising in 10 mM
Tris.HCI, pH 7.6, containing 0.2 mM MgC92. Isolated nuclei
(about 90% of the large particles present) were quickly
diluted in isoton and particle diameter was determined as
described above for cell diameters.
Cellular doxorubicin amounts present at different IC5o
values in SW-1573/MDR cells were corrected for their
differences in cell volume compared to SW-1573 parent cells
using the following formula:
doxi
=dox, + VC (SW-1573) x dox, (SW-1573/MDR)
Vc, (SW-I573/MDR)
Doxi is the corrected cellular doxorubicin amount in SW-
1573/MDR cells. Nuclear doxorubicin (dox.) at the IC50 was
estimated to be about 8 pmol 106 cells and assumed to be a
constant value for all SW-1573 cells as explained under
Results (first section). V. means cytoplasmic volume and was
calculated from nuclear and cellular diameters (see text
Results section + Table I). Cytoplasmic doxorubicin (dox,)
was calculated by subtracting the fixed value of 8 pmol 106
cells from the total cellular doxorubicin amounts measured at
each IC5o value using radiolabelled doxorubicin (shown under
Results in Figure 6).
Quantification ofdrug distribution with laser scan microscopy
Quantification of ratios of nuclear doxorubicin fluorescence/
cytoplasmic doxorubicin fluorescence (N/C ratio) with laser
scan microscopy and image analysis was performed as des-
cribed (De Lange et al., 1992; Schuurhuis et al., 1989a).
Adhered MDR and sensitive cells were incubated for 2 h at
37°C at the same concentrations of doxorubicin and/or
verapamil that would result in the different IC50 values found
in the cytotoxicity assay. For each treatment in a particular
experiment 30-50 cells were measured unless indicated other-
wise. Total nuclear amounts of doxorubicin were calculated
from ratios nuclear doxorubicin/cytoplasmic doxorubicin (N/
C fluorescence ratios, but now corrected for doxorubicin
fluorescence quenching by DNA as outlined in the next
paragraph) and from [14-'4C] doxorubicin accumulation
experiments (giving total cellular doxorubicin amounts) at the
doxorubicin and verapamil concentrations of interest.
For direct comparison of relative fluorescence signals in
AUXB1 and CHRC5 cells, these cells were allowed to grow
on petri dishes in close proximity. This enabled fluorescence
recording under the same optical and instrumental condi-
tions. Fluorescence was recorded in at least ten cells in each
experiment.
Quenching ofdoxorubicinfluorescence
In order to be able to calculate total nuclear amounts of
doxorubicin in intact cells using N/C doxorubicin
fluorescence ratios and total cellular amounts as determined
with radiolabelled doxorubicin (see previous paragraph), the900 G.J. SCHUURHUIS et al.
percentage fluorescence quenching in nuclei needs to be
determined. For that purpose isolated nuclei of AUXB1 and
CHRC5 cells were prepared by incubating intact cells in
hypotonic medium (10 mM Tris.HCI containing 2 mM MgCl2,
pH 7.6) for 30 min on ice and subsequent homogenising by
pottering. The nuclei were resuspended in growth medium
(see under Drug accumulation). The fluorescence signal of
2jLM doxorubicin in medium of 37°C in a 1 ml cuvet (Io) was
determined using a spectrofluorometer (FluoroMaxTM from
SPEX Industries, Edison, NJ). Aliquots of nuclei (3.107 ml- )
were added to the cuvet. The fluorescence signal decreased as
a result of quenching due to intercalation into DNA. Extra
aliquots of nuclei were added until the fluorescence signal
(originating partly from nuclei- associated and partly from
some remaining extra-nuclear fluorescence) had stabilised
(I,). The percentage quenching of doxorubicin in the nuclei
could be calculated from the decrease of the initial
fluorescence of doxorubicin. The fluorescence signal was cor-
rected for (i) the autofluorescence of the particular number of
nuclei used (12) and (ii) the remaining extranuclear doxo-
rubicin fluorescence (13), which was determined by centrifug-
ing the nuclei in the cuvet (without washing) and measuring
the fluorescence of the supernatant. Nuclear doxorubicin
fluorescence is now I-I2-I3, while total nuclear doxorubicin
(fluorescent plus non-fluorescent) is Io-I3. Fluorescent doxo-
rubicin as a percentage of the total amount of doxorubicin in
the nuclei can thus be calculated from:
[(II-12)- 131/[Io-13] x 100. The ratio was 8.5 ± 1.4%
(mean ± s.e.m. of two independent experiments, each deter-
mined in triplo, for nuclei of both cell lines. No quenching of
doxorubicin in non-nuclear cellular compartments was
assumed to occur (Tarasiuk et al., 1989).
Results
Relationship between IC50 and drug accumulation at IC50
As for many MDR cells with P-glycoprotein, verapamil
caused a dose-dependent decrease of IC50 in the human non-
small cell lung cancer MDR cells SW-1573/1R500 as illus-
trated in Figure 1 (ordinate). Doxorubicin resistance could
not be reversed completely (residual level of resistance was
about 7) at least partly because concentrations of verapamil
higher than 128gM could not be used due to unacceptable
toxicity in the 24 h incubation assay with verapamil. When
cellular doxorubicin accumulation was determined in a 2 h
incubation assay at the actual IC50 values obtained (e.g.
32tLM doxorubicin with no verapamil present and 1 tLM
doxorubicin with 24 ,UM verapamil present), a linear relation-
ship was found when IC50 values were plotted on a logarith-
mic scale against cellular doxorubicin amounts measured at
these IC50 values (Figure 1). This shows that reversal of
resistance can be described by a function of the type
IC50 = ec4doxi at IC50]
in which c is a constant and doxi is the cellular amount of
doxorubicin at each IC50 value. The figure shows that (i)
intracellular doxorubicin is very ineffective in inhibiting cell
growth in SW-1573/1R500 cells when no verapamil is present
(490 pmol 10-6 cells were necessary to reach IC50 compared
to about 14 pmol 10 6 cells in the parent cell line SW-1573)
and (ii) verapamil drastically increases the efficacy of dox-
orubicin in the MDR cells (only about 80 pmol 106 cells are
necessary to reach IC50 when 128 .LM verapamil is present).
For the human breast cancer cell line MCF-7ADR similar
results were obtained (Figure 2). The ability of verapamil to
increase the efficacy of doxorubicin must be added to its
well-known action on drug accumulation perse at a fixed
doxorubicin concentration and which is illustrated in Figure
3 for MCF- 7ADR cells. The verapamil-induced change of
efficacy predominates at low residual levels of resistance
(>32pM verapamil) where IC50 decreases (Figure 2) despite
the fact that doxorubicin accumulation is already maximal at
3201M verapamil (Figure 3). It should be noticed that extra-
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Figure 1 Relationship between logIC50 and cellular doxorubicin
at IC_0 in SW-1573/1 R500 cells. Doxorubicin IC50 was determined
in a 2 h incubation with doxorubicin in the presence of the
indicated concentrations (O-128 !M) of verapamil (Vp) as des-
cribed under Materials and methods. Cellular amounts of dox-
orubicin at the doxorubicin IC50 values thus found were
measured under the same conditions in a 2 h incubation assay
(see Materials -and methods). 0, SW-1573/lR500 minus
verapamil; 0 0, SW-1573/1 R500 plus verapamil. The
parent cell line SW-1573 is indicated by an open square. The
figure shows a representative cytotoxicity experiment (carried out
in duplicate) and accumulation experiment (carried out in trip-
licate). Bars represent s.e.; no bars are present if s.e. is smaller
than the symbol. Correlation coefficient is 0.992 for data obtained
with 0- 128 IM verapamil. Dx, doxorubicin; Vp, verapamil.
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Figure 2 Relationship between logIC50 and cellular doxorubicin
at IC50 in MCF-7ADR cells. Doxorubicin IC50 and accumulation
data were obtained as described for SW-1573/1 R500 cells in
Figure 1. 0, MCF- 7ADR minus verapamil; 0 0, MCF-7ADR
plus verapamil; 0, the parent cell line MCF-7. Data shown are
means ± s.e. for two independent cytotoxicity and accumulation
experiments each carried out in duplicate and triplicate, respec-
tively. Correlation coefficient is 0.997 for data obtained with
8-128 ±M verapamil and 0.98 with 0- 128IM verapamil. How-
ever, accumulation values at 0jAM verapamil likely have been
overestimated as a result of excessive sticking of doxorubicin to
the cells at the very high (290JuM) concentration used. Dx, doxo-
rubicin; Vp, verapamil.
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Figure 3 Verapamil-induced stimulation of doxorubicin accumu-
lation in MCF-7ADR cells. Doxorubicin accumulation was
measured on trypsinised MCF-7ADR and MCF-7 cells as described
under Materials and methods at a fixed concentration of doxo-
rubicin (0.5 JM) after a 2 h incubation period as a function of the
verapamil concentration. 0 *, MCF-7ADR, 0 0, MCF-7.
Shown is a particular experiment in which each point represents
mean ± s.d. of triplicate samples. Vp, verapamil.
polated straight lines, which would predict results obtained
with infinitely high concentrations of verapamil, did not cross
the coordinates found for the sensitive cell lines (Figures
and 2).
The revertant cell line SW-1573/1R500-0, used because of
its intermediate level of doxorubicin resistance (24-fold),
shows similar characteristics (Figure 4). The use of 128pM
verapamil resulted in a residual level of doxorubicin resis-
tance of a factor 2 (Figure 4). For this cell line, however,
deviations from linearity in the semilogarithmic plot occurred
at higher (8-128 tM) verapamil concentrations (see broken
curve).
When the data shown in the Figures 1, 2 and 4 were
plotted on a linear scale, part of the curve that describes the
remaining doxorubicin resistance at high verapamil concent-
rations turned out to be a straight line (Figures 5 and 6).
Strikingly, extrapolation to complete reversal of resistance
showed that the line now almost crosses the origin as well as
the coordinates of the sensitive SW-1573 and MCF-7 cells
(Figures 5a and b, respectively). Thus at least the last part of
reversal of resistance can be described by the simple func-
tion
IC50 = c.[doxi at IC50]
in which c is a constant and doxi is the cellular amount of
doxorubicin at each IC50 value. In SW-1573 variants that
show a MDR phenotype without overexpression of P-
glycoprotein (Baas et al., 1990; Kuiper et al., 1990) the same
relationship was found (Figure 6).
The minimal cellular amount of doxorubicin necessary to
reach IC50 was 8 pmol 10-6 cells as found for SW-1573 cells
in the presence of verapamil (see Figure 6). Since the
majority of doxorubicin in sensitive cells is present in the
nucleus (Seeber et al., 1980), the nuclear amount of dox-
orubicin necessary to reach IC50 was approximately
8 pmol 106 cells.
For the SW-1573/1R500-0 cells the curve did not cross the
coordinates found for the sensitive SW-1573 cells (Figure 6).
When, however, the intracellular doxorubicin amounts at
IC50 were corrected for the cytoplasmic volume (which is
relatively large in this cell line; see Table I) in a way de-
scribed under Materials and methods and in the legends of
Figure 6, a corrected line was obtained which now closely
approaches the coordinates of the sensitive cell line. Only
small corrections due to differences in cellular volume
between sensitive and resistant cells were necessary for the
other cell lines including MCF-7 cells (Table I). Corrected
lines are therefore not shown in the Figures.
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Figure 4 Relationship between logIC50 and cellular doxorubicin
at IC50 in revertant SW-1573/lR500-0 cells. Doxorubicin IC50 and
accumulation data were obtained as described for SW-1573/
1R500 cells in Figure 1. Open symbols: no verapamil present;
closed symbols: with verapamil. V, V: SW-1573/lR500-0 cells;
0, 0: the parent cell line SW-1573. For SW-1573 cells only
32tLM verapamil was used. Data are means ± s.d. of three
independent experiments each performed in duplicate or trip-
licate. Correlation coefficient is 0.989 for data obtained with
0-32t4M verapamil in SW-1573/1R500-0 cells. Broken curved line
indicates possible extrapolation to sensitive (SW-1573) coor-
dinates. Dx, doxorubicin; Vp, verapamil.
Doxorubicin N/Cfluorescence ratios in sensitive and MDR
cells
Previously we have presented evidence that the increased
amounts of intracellular doxorubicin at IC50 in MDR cells
and the verapamil-induced reversal of this process results
from changes in intracellular distribution of doxorubicin
(Schuurhuis et al., 1989a). We now have measured similar
resistance-related and/or verapamil-induced changes in the
ratio nuclear doxorubicin fluorescence and cytoplasmic doxo-
rubicin fluorescence in human MDR cancer cell lines (Table
II). Figure 7 illustrates doxorubicin fluorescence distribution
in the 2780 ovarian cancer cell lines in the presence of
different concentrations of verapamil. In parental A2780 cells
relatively little fluorescence is present in the cytoplasm
(Figure 7a). This situation is not altered when verapamil is
used (Figure 7b). In contrast, resistant 2780AD cells contain a
relatively large fraction of the total cellular fluorescence in
the cytoplasm, either as a diffuse Golgi-like cloud or in a
punctuate pattern throughout the cytoplasm (Figure 7c).
Verapamil in increasing concentrations increases the percen-
tage of cells with preferential nuclear fluorescence localisation
(compare situation in the absence of verapamil in Figure 7c
with d and e, which illustrate the effects of 4 and 8gM
verapamil, respectively). In the presence of 128 LM of
verapamil almost all cells showed preferential nuclear
fluorescence (illustrated in Figure 7f). The situation was not
completely the same as in the sensitive cell line, since residual
punctuate cytoplasmic fluorescence was still present.
Qualitatively similar results were found for the other cell
lines used (not shown here). Of particular interest doxo-
rubicin fluorescence distribution in SW-1573/1R50 cells,
which do not overexpress P- glycoprotein (Baas et al., 1990),
could not be modulated with verapamil similar to the situa-
tion for other non-P-glycoprotein/MDR cell lines (Schuur-
huis et al., 1991).
Nuclear amounts ofdoxorubicin at equitoxic concentrations
In Figure 8 it is shown that intracellular doxorubicin
amounts at IC50 are increased in the MDR Chinese hamster
cells and can be decreased by verapamil in a dose-dependent
way as shown in this paper for other MDR cells. The photo-
graphs in Figure 9 further illustrate that this is most prob-
ably largely due to a verapamil-reversible increase of cyto-
plasmic doxorubicin during development of resistance. On
v902 G.J. SCHUURHUIS et al.
32
7.0
4.0
00*
/2*
Ca
3.2 F
2.4 /
2.0 /*8*
1.6
1.2 *16*
0.8 ., 64* SW-1573/1R500
128* *:Vp (>M)
0.4
SW-1573 r 0.999
0 40 80 120 160 200 240 280 490
370
290 [
3.2
2.8
2.4
2.0
1.6
1.2
0.
0.
.8
.4
o 0*
/
LT I g_ Zf-2 32* li4f64
- 128*
A MCF-7 1
- '.
0 40 80
MCF-7ADR
*:VP (LM)
r= 0.997
120.
120 160 3540
Cellular Dx (pmol 10-6 cells) at IC50
Figure 5 Relationship between IC50 and cellular doxorubicin at IC50 in SW-1573/IR500 and MCF-7ADR cells. Data from the
Figures 1 and 2 were replotted on a linear scale in Figure 5a (SW-1573/IR500 and SW-1573) and Figure Sb (MCF-7ADR and
MCF-7), respectively. For Figure 5a correlation coefficients were 0.999 for data obtained with 8- 128 g1M verapamil. The same was
found when the data for the parent cell line SW-1573 and the origin (0,0) were included. 0, SW-1573/lR500 minus verapamil;
0 0, SW-1573/lR500 plus verapamil; 0, the parent cell line SW-1573. for Figure 5b the correlation coefficient was 0.997 for
data obtained with 32-128 gm verapamil. The same was found when the data for the parent cell line MCF-7 and the origin were
included. 0, MCF-7ADR minus verapamil; *, MCF- 7ADR plus verapamil; 0, the parent line MCF-7. Dx, doxorubicin; Vp,
verapamil.
the other hand the photographs in Figure 9 also illustrate
that the nuclear doxorubicin fluorescence, measured at
equitoxic concentrations, may vary much less over the whole
range of reversal of resistance. As a result of these processes
total cellular fluorescence was much higher in CHRC5 cells
without verapamil than in AUXB1 cells without verapamil
(factor > 13), when measured under equitoxic conditions
(700liM and 1 lIM, respectively, corresponding to the Figures
9f and a, respectively) and when using the method that
enabled direct comparison of fluorescence signals (see
Materials and methods under 'quantification of drug dist-
ribution with laser scan microscopy'). This difference was
reduced to a factor 9.7 ± 4.3 (n = 3) under conditions illus-
trated in Figure 9e. A further reduction to 2.7 ± 1.4 (n = 3)
was found using 8 JLM doxorubicin plus 4iLM verapamil
(Figure 9d). At complete reversal of resistance total cellular
fluorescence was only a factor 1.2 ± 0.3 (n = 3) higher than in
AUXB1 cells.
No quenching of cytoplasmic fluorescence has been
assumed to occur (see Materials and methods; Tarasiuk et
al., 1989). Recently, however, a possible concentration-
dependent quenching of daunorubicin in denucleated cells
has been reported (Slapak et al., 1992). Consequently, at the
higher drug concentrations (e.g. > 3 ILM in Figure 8), C-
values may have been underestimated. The measured N/C
ratios and thereby the calculated N-values may thus have
been overestimated. This would fit even better with the conc-
lusion that N-values are constant irrespective residual resis-
tance levels.
Unfortunately, determination of N/C ratios was inaccurate
especially at higher levels of resistance because part of the
cytoplasmic fluorescence overlapped the nuclear fluorescence.
As a result the N value in the N/C ratio, and thereby the
calculated total nuclear doxorubicin amounts, will be overes-
timated at the higher levels of resistance. Nevertheless Figure
8 shows that at complete reversal of resistance (32 IM
verapamil) the calculated nuclear drug amounts are the same
as in AUXB1 cells.
Discussion
From the literature it appears that there is almost consensus
about the fact that multidrug resistance is multifactorial. For
example, the factors mentioned to contribute to anthracycline
or VP-16 resistance in MDR cells include decreased drug
accumulation, caused by changes in drug influx and/or drug
efflux (Bradley et al., 1988) and mostly parallelled by changes
in the intracellular distribution of the drug (Broxterman et
al., 1990; Gervasoni et al., 1991; Gigli et al., 1989; Hinden-
burg et al., 1987, 1989; Keizer et al., 1989; Schuurhuis et al.,
1989a, 1991; Willingham et al., 1986), changes in topoiso-
merase II activity/levels (Beck, 1989) or alterations in drug
activation or in the capacity to detoxify reactive drug-
induced oxygen-derived free radicals (Sinha & Mimnaugh,
1990). In the present paper we have made an analysis of
factors contributing to drug resistance in MDR cells by the
use of a quantitative approach.
First we have shown that development of doxorubicin
resistance in human lung cancer and human breast cancer
cells is characterised by an increase in cellular amounts of
drug measured at equitoxic drug concentrations. Apart from
this decrease in drug efficacy it is known that these cells have
a decreased drug accumulation compared to parent cells
when exposed to a fixed external concentration of drug. This
is due, at least for a part, to the presence of the putative drug
P-glycoprotein efflux pump in these cells (Fairchild et al.,
1987; Keizer et al., 1989). The decrease in drug efficacy might
in principle be caused by factors such as alterations of
glutathione transferase activity as mentioned above. How-
ever, an agent like verapamil, known for its potent stimula-
tion of drug accumulation in such P-glycoprotein-containing
cells (Bradley et al., 1988; Ford et al., 1988; Keizer et al.,
1989; Politi et al., 1990) turned out to be active in reversing
the decreased doxorubicin effectiveness as well (Figures 1, 2
and 4-6). As will be explained below it is unlikely that
verapamil exerts this action via an effect on other factors
a b
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(such as glutathione transferase activity) mentioned earlier to
contribute to doxorubicin resistance.
For the high level MDR cell lines it was found that
reversal of resistance can be described by a function of the
type
IC5o = ec[doxi at 1C50]
in which c is a constant.
This relationship is applicable to moderate to high levels of
residual resistance, i.e. resistance left upon verapamil
exposure. At low to moderate residual levels of resistance the
data fit into a simpler function:
IC50 = c.[doxi at IC50]
in which c is a constant.
In Figure 10 a simple model is depicted which may explain
the relationships found between IC50 and [doxi at IC50]. If
3.0-
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2.0
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0.8 +
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,/ ,./ ~~4*
O0.6 ~~/ ,, r, 0.6 i .
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32*
,I/ 128*
r> 0.99
0 40 80 120 160 200
Cellular Dx (pmol 10-6 cells) at IC50
Figure 6 Relationship between IC50 and cellular doxorubicin at
IC5o in SW-1573/1R500-0, SW-1573/1R50 and SW-1573/2R30
cells. Data from Figure 4 were replotted on a linear scale. In
addition, data obtained for the non-P-glycoprotein/MDR cell
lines SW-1573/2R30 and SW-1573/IR50 are added. Open sym-
bols, no verapamil present; closed symbols, plus verapamil (321AM
in SW-1573, SW-1573/1R50 and SW-1573/2R30 cells). V, 7:
SW-1573/1R500-0 cells; 0, *: SW-1573/1R50 cells; A, A: SW-
1573/2R30 cells; 0, 0: parental SW-1573 cells. The correlation
coefficient was >0.99 for SW-1573/1R500-0 cells for data
obtained with 2-128 1AM verapamil, also when the origin was
included. The same was found for SW-1573/lR50 and SW-1573/
2R30 cells. Note that coordinates of origin, SW-1573 cells minus
verapamil (0) and the non-P-glycoprotein/MDR cells (0, A)
indicate a linear relationship between IC50 and cellular doxo-
rubicin at IC50 in SW-1573/2R30 but not in SW-1573/1R50
cells.
The data obtained for SW-1573/IR500-0 cells when cellular
amounts of doxorubicin had been corrected for cytoplasmic
volume are shown too (*- *; r>0.99, when now also the
coordinates of SW-1573 cells were included). Corrections were
made using the formula shown under Materials and methods. It
is assumed that nuclear amounts of doxorubicin are the same at
all IC50 values fnd for SW- 1573 and SW-1573/lR500-0 cells,
which is highly likely as explained in the Results section under
'nuclear amounts of doxorubicin at equitoxic concentrations'.
For reference to residual levels of resistance in the highly resistant
cell line SW-1573/lR500, the last part of Figure 5a (at dox-
orubicin concentrations <1 1AM) is indicated ( ....). Dx,
doxorubicin; Vp, verapamil. In the inset it is shown that at
verapamil concentrations <21AM deviations from linearity occur
in SW-1573/lR500-00 cells similar to those seen at low verapamil
concentrations in Figure 5.
reversal of resistance by verapamil would have been caused
solely by stimulation of drug accumulation, [doxi at IC50]
would have been constant in the presence or absence of
different concentrations of verapamil (line I in Figure IOA).
On the other hand, if hypothetically the verapamil-induced
reversal of resistance would not be parallelled at all by a
stimulation of drug accumulation, [doxi at IC50] should be
lower in the presence of verapamil (line II in Figure IOA).
With this in mind the shape of the curves as shown in the
Figures 5 and 6 can easily be explained assuming that
verapamil shows both effects at residual resistance levels of
> 17 (SW-1573/1R500), >6 (MCF-7ADR) and >7.5 (SW-
1573/lR500-0), while at residual resistance levels of 7-17
(SW-1573/lR500), 4-6 (MCF-7ADR) and 2-7.5 (SW-1573/
1R500-0) it acts almost exclusively via its accumulation-
independent effect.
In the 7.4-fold resistant SW-1573/1R50 cells, which do not
express P-glycoprotein (Baas et al., 1990), an accumulation
defect of 1.6 was found (not shown), indicating that
emergence of resistance in these cells occurred both via a
decrease of drug accumulation and a decrease of drug
efficacy. This is compatible with the observation that a curve
which would include the coordinates of the origin, SW-1573
(minus verapamil) and SW-1573/1R50 (minus verapamil) (see
Figure 6) would be intermediate between lines I and II in
Figure lOB. In contrast, the coordinates of origin, SW-1573
cells minus verapamil and SW-1573/2R30 cells minus
verapamil (Figure 6) indicate a close-to- linear relationship
between IC50 and [doxi at IC50]. This shows that a change of
doxorubicin efficacy may be the main or only factor responsi-
ble for the low degree of doxorubicin resistance in these cells
Figure 7 Subcellular doxorubicin fluorescence distribution in
2780 human ovarian cancer cells in the presence of different
concentrations of verapamil. A2780 parental and 2780ADMDR
cells were incubated for 2 h at 37'C with doxorubicin and with
different concentrations of verapamil. In order to improve detec-
tion of fluorescence in nucleus and cytoplasm, doxorubicin con-
centrations were used that resulted in about equal intracellular
amounts at all combinations used. a, A2780; 41M doxorubicin,
no verapamil; b, A2780; 41AM doxorubicin, 321AM verapamil.
c, 2780AD, 201AM doxorubicin, no verapamil. d, 2780AD; 151AM
doxorubicin, 41AM verapamil. e, 2780AD; 10 1AM doxorubicin, 81AM
verapamil. f, 2780AD; 5 1AM doxorubicin, 321lM verapamil. Note
mainly nuclear localisation of fluorescence in a, b, e and f and
mainly cytoplasmic localisation of fluorescence in c and d. Inci-
dentally cells with mainly nuclear localisation can be observed
under conditions illustrated in d (arrowhead); incidentally cells
with mainly cytoplasmic fluorescence localisation can be seen
under conditions illustrated in e (arrowhead). Bar in a, indicates
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Table I Cellular and nuclear diameters of MDR and sensitive cells
Cell line
SW-1573
SW-1573/1R500
SW-1573/1R500-0
AUXB1
CHRC5
MCF-7
MCF-7ADR
d cell ("im)
16.15 ± 1.20a(9)b
16.82 ± 1.31 (9)
17.92 ± 0.70c(7)
12.96± 0.31 (4)
13.69 ± 1.35 (4)
16.20 ± 1.64 (4)
16.41 ± 0.83 (4)
Calculated
d nucleus (#m) cytopl. vol. (jim3)
10.47 ± 0.84 (3) 1606
10.54 ± 0.97 (4) 1877
10.54 ± 1.54 (2) 2399
aMean ± s.d. bValues in parenthesis indicate number of independent experiments.
cSignificantly different from SW-1573 value (P <0.01, Student's t-test). -, not
determined.
Table II Subcellular doxorubicin fluorescence distribution in human breast, lung and ovarian cancer
MDR and sensitive cell lines
Modifier IC50a [doxi at IC50a]
Cell line (AiM) (fM) (pmolJ06 cells) N/C ratiob
MCF-7 None 0.19 16 exp.1: 3.6± 1.1
exp.2: 3.2 0.9
MCF-7ADR None 290 3542 exp.l: 0.1 ± 0.1
exp.2: 0.1 ± 0.1
16Vp 1.8 99 exp.i: 0.8 0.3
128 Vp 0.75 46 exp.i: 2.5 0.8
exp.2: 1.3 0.7
SW-1573 None 0.11 13.5 2.8 0.1 (n =3)
SW-1573/1R500 None 38 490 0.3 ±0.3
8Vp 2 220 1.7±1.5
128 Vp 0.75 80 2.2 1.0
SW-1573/1R500-0 None 2.6 448 1.2 ± 0.7
128Vp 0.21 43 2.5 1.1
SW-1573/1R50 None 0.78 63 1.9 0.1* (n =4)
32 Vp 0.37 28 1.8 0.1
A2780 None 0.24 24 2.9 1.2
2780AD None 17.4 128 0.4 ± 0.2
32 Vp 0.45 35 2.7 1.0
aMean of 2-7 independent experiments (s.s. <20%). bMean (± s.s.) of at least 30-50 cells in a
representative experiment, except in the case of MCF-7 and MCF-7ADR cells (two independent
experiments as indicated; each 30-50 cells) and SW-1573 and SW-1573/I R50 cells (given are M ± SD
of 3-4 independent experiments). *Significantly different from N/C ratio of SW-1573 parent cells
(P<0.01, Student's t-test).
N/C ratios were determined at IC50 values of doxorubicin except for the sensitive cells or when
verapamil (Vp) was used (in those cases 2 M doxorubicin was used since at lower concentrations
background noise became too high). N/C ratios are independent of doxorubicin concentration in a
large range of drug concentrations (De Lange et al., 1992), suggesting that this is also the case at
concentrations lower than 2pM.
(compare with line II in Figure lOA and B. This has been
confirmed in accumulation experiments performed at a fixed
(0.5;iM) doxorubicin concentration which revealed no
accumulation defect (not shown).
Continuous exposure of SW-1573/2R30 cells to doxo-
rubicin led to isolation ofSW-i573/2R50 cells, which are ofa
non-P- glycoprotein MDR phenotype (Baas et al., 1990;
Kuiper et al., 1990) and after prolonged exposure to cells
with an increased mdr-I mRNA and P-glycoprotein expres-
sion (Kuiper et al., 1990). Similar results have been found for
murine erythroleukaemia cells (Slapak et al., 1990). It could
thus be that doxorubicin resistance in low level MDR non-P-
glycoprotein lung cancer cells as well as doxorubicin resis-
tance of early selected cells of the high level MDR P-glyco-
protein cell lines MCF-7ADR and 2780AD, is caused, at least
partly, by the same P-glycoprotein-independent phenotypic
change that occurs in P-glycoprotein-mediated resistance, i.e.
a change in intracellular drug efficacy, which would, at least
partly, be caused by a change in subcellular drug distribu-
tion.
In the present study it is shown that a partial reversal of
doxorubicin resistance was accomplished in human MDR
cells which was accompanied by a partial reversal of N/C
ratio changes (Table II). Complete reversal of doxorubicin
resistance in CHRC5 P-glycoprotein/MDR Chinese hamster
ovarian cells to parental AUXB1 levels was accompanied by
a complete reversal of the drug accumulation defect as well
as the drug distribution change (Schuurhuis et al., 1989a).
The consequence of these findings would be that it is mainly
if not only the nuclear concentration of drug which deter-
mines sensitivity/resistance. For CHRC5 cells we confirmed
this relationship (Figures 8, 9). It cannot be excluded, how-
ever, that verapamil acts via a mechanism comprising incre-
ment of nuclear doxorubicin efficacy. This mechanism of
resistance reversal might prevail in non-P-glycoprotein MDR
cells. The fact that considerable decrease of doxorubicin
resistance in such cells by verapamil is possible with only
small concomitant changes of drug accumulation or drug
distribution (this paper; Schuurhuis et al., 1991), are in
favour of this idea. The results presented in the present paper
for P-glycoprotein MDR cells are nevertheless in agreement
with a paper of Gigli and colleagues, who did not study
verapamil effects, but, making use of spectral properties of
doxorubicin, showed that nuclear concentrations of doxo-
rubicin were not significantly different at equitoxic drug con-
centrations in sensitive and resistant K562 human leukaemia
cells (Gigli et al., 1989). Also, in a study comparing cellular
doxorubicin accumulation, cytotoxicity and DNA lesions in
sensitive and multidrug-resistant human myeloma cells, Bel-
lamy et al. showed that at low doxorubicin concentrations
important for cytotoxicity, equal cellular concentrations in
both sensitive and resistant cells, obtained by adjustment of
extracellular drug concentrations, nevertheless caused less
cytotoxicity in resistant cells (Bellamy et al., 1988b). DNASUBCELLULAR DRUG DISTRIBUTION IN MULTIDRUG RESISTANCE
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Figure 8 Interrelationship between IC50, cellular doxorubicin at IC50 and nuclear doxorubicin at IC50 in adherent CHRC5 and
AUXB1 cells. IC50 values were obtained in an assay including a 2 h incubation with doxorubicin as described under Materials and
methods. Total cellular amounts of doxorubicin at IC50 obtained with different concentrations of verapamil were determined in a
2 h incubation assay using ['4C]-labelled doxorubicin as described under Materials and methods. Nuclear amounts of doxorubicin
were calculated from N/C fluorescence ratio measurements with laser scan microscopy (corrected for fluorescence quenching by
DNA as described under Materials and methods) and from the accumulation experiments described above (giving total cellular
amounts of doxorubicin). Open symbols: measured cellular amounts of doxorubicin in CHRCS cells (0 O) and AUXBI cells
(0); closed symbols: calculated nuclear amounts of doxorubicin in CHRC5 cells ( --- 0) and AUXB1 cells (M). Doxorubicin
amounts are in pmol 10-6. No verapamil was used for AUXB1 cells. Data are means ± s.d. from 3-9 independent cytotoxicity,
accumulation and N/C fluorescence ratio measurements. The numbers a, c-f refer to the photographs shown in Figure 9.
damage in the resistant cells was also less under these condi-
tions (compare Bellamy et al., 1988a and b). This is in good
agreement with the observation that N/C ratios are lower in
these resistant cells (De Lange et al., 1992; Broxterman et al.,
1990). This suggests, as outlined extensively in the present
paper, that higher cellular concentrations are needed in the
resistant cells in order to obtain the same nuclear concentra-
tions as in sensitive cells.
It has to be stated that other reversing agents behave in a
way similar to verapamil: bepridil, Ro 11-2933/001 and
Cremophor EL have been tested as to this (Schuurhuis et al.,
1989a, 1990a). None of the modifiers, even at high concentra-
tions, was able to overcome completely accumulation defects
in human MDR cells (see e.g. Schuurhuis et al., 1990b).
Verapamil has been used mainly because it is less toxic than
several other reversing agents and because it is the most
widely studied reverter.
Figure 9 Subcellular doxorubicin fluorescence distribution in the
presence or absence of verapamil at equitoxic concentrations in
CHRC5 and AUXBI cells. Adhered cells were incubated for 2 h
at 37°C with combinations of different concentrations of doxo-
rubicin and verapamil, as specified below, which all resulted in
the same growth-inhibition. Doxorubicin concentrations used
were in all cases 2.5 times higher than the IC,0 values, shown in
Figure 7, since otherwise the fluorescence in nucleus and/or
cytoplasm could hardly be visualised and quantified. Viability as
determined with the trypan blue exclusion test remained >99%
for at least 12 h when cells were incubated without any drug
present after the 2 h period in the presence of doxorubicin and/or
verapamil. a and c-f: fluorescence microscopy; b: phase contrast
microscopy. a, AUXB1, 1 JM doxorubicin without Vp. b,
AUXB1, same cells as in a, phase contrast. c, CHRC5, 1 JAM
doxorubicin plus 32gM Vp. d, CHRC5, 8JLM doxorubicin plus
4 JAM Vp. e, CHRC5, 50gM doxorubicin plus 2JAM Vp. f, CHRC5,
700 JAM doxorubicin without Vp. N, nucleus; C, cytoplasm; Dx,
doxorubicin; Vp, verapamil. Bar in a indicates 20JLm.
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Figure 10 Theoretical relationship between IC50 and cellular doxorubicin measured at IC50 assuming that two factors contribute to
doxorubicin resistance and that two modes of action of verapamil exist. A, Reversal of resistance by verapamil occurs solely by
stimulation of drug accumulation (I) or solely by changing the efficacy of cellular doxorubicin (II). B, Emergence of resistance
occurs solely by a decrease of drug accumulation (I) or solely by changes in efficacy of cellular doxorubicin (II).
Apart from MDR Chinese hamster ovarian (this paper;
Schuurhuis et al., 1989a), human ovarian cancer (this paper;
Schuurhuis et al., 1989a), human lung cancer (this paper;
Keizer et al., 1989) and human breast cancer (this paper;
Gervasoni et al., 1991) cells, also P-glycoprotein containing
KB (Willingham et al., 1986), human myeloma (Broxterman
et al., 1990) and human leukaemia (Gigli et al., 1989) cells
show changes in subcellular drug distribution in addition to
changes in cellular drug accumulation. It is therefore tempt-
ing to speculate that the relatively simple explanation for
doxorubicin resistance in P-glycoprotein/MDR cells, includ-
ing the two factors depicted in this paper, is generally ap-
plicable.
It has been speculated that changes in free radical detoxify-
ing enzymes such as glutathione transferase and glutathione
peroxidase contribute to doxorubicin resistance in P-
glycoprotein/MDR MCF-7ADR cells (Batist et al., 1986;
Cowan et al., 1986; Sinha et al., 1987; Sinha & Mimnaugh,
1990). From our results, however, it appears that also in
MCF-7 MDR cells decreases in drug accumulation together
with changes in drug distribution can largely account for
doxorubicin resistance. This conclusion is based on proven
effects of verapamil on drug accumulation and drug distribu-
tion. We have found no anomalous effects of verapamil on
glutathione transferase, which might have coincided with resis-
tance reversal: this enzyme (48-fold increased in MCF-7ADR in
our hands) was not affected by verapamil concentrations as
high as 1 mM (not shown). Such verapamil concentrations are
beyond those calculated to occur in cells using effective
verapamil concentrations (Broxterman et al., 1988; Cano-
Gauci & Riordan, 1987; Yusa & Tsuruo, 1989). Verapamil
also had no effect on glutathione peroxidase activity (Batist
et al., 1991). Lastly, it has been found that transfection of the
gene encoding for glutathione transferase did not confer
resistance to doxorubicin (Moscow et al., 1989). Since
changes in expression of enzymes suggested to be involved in
detoxification of xenobiotics apparently are not involved in
doxorubicin resistance we speculate that transfection of the
gene encoding for glutathione peroxidase will not confer
resistance to doxorubicin in MCF-7 or other parental cell
lines.
Upon the mechanism by which MDR cells acquire an
altered subcellular drug distribution can only be speculated.
Small amounts of P-glycoprotein present on the membranes
of cytoplasmic vesicles (Willingham et al., 1987) might force
the drug into the vesicles. Alternatively, a drop in vesicular
pH, probably parallelling an increase of the cytoplasmic pH
under certain conditions (Keizer & Joenje, 1989; Thiebaut et
al., 1990) or an increase of the vesicular compartment
(Sehested et al., 1987) might explain higher drug accumula-
tion in cytoplasmic compartments, resulting in decreased N/
C ratios.
In conclusion, the results presented in this paper show
that, at least in P-glycoprotein MDR cells, changes in drug
accumulation together with changes in subcellular drug dist-
ribution largely account for doxorubicin resistance, thereby
excluding the need to postulate additional mechanisms for
these cell lines.
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Abbreviations: DMF, dose modifying factor = IC.0 minus resis-
tance modifier/IC50 plus resistance modifer; Dx, doxorubicin; IC50 =
drug concentration, which inhibits cell growth by 50% of control
values; MDR, multidrug resistant/resistance; Vp, verapamil.
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